SMARCA4 and intestinal cancer: The SWI/SNF status represents another significant difference between primary rhabdoid intestinal cancer (where loss of SMARCB1, ARID1A, and SMARCA4 was observed collectively in 69% of cases [3, 4]), and metastatic undifferentiated NSCLC with no loss of SMARCB1/ARID1A and only rare SMARCA4 loss being observed in our series.